163 related articles for article (PubMed ID: 22614243)
41. Monascuspiloin induces apoptosis and autophagic cell death in human prostate cancer cells via the Akt and AMPK signaling pathways.
Chen RJ; Hung CM; Chen YL; Wu MD; Yuan GF; Wang YJ
J Agric Food Chem; 2012 Jul; 60(29):7185-93. PubMed ID: 22738037
[TBL] [Abstract][Full Text] [Related]
42. Combination therapy using Notch and Akt inhibitors is effective for suppressing invasion but not proliferation in glioma cells.
Jin R; Nakada M; Teng L; Furuta T; Sabit H; Hayashi Y; Demuth T; Hirao A; Sato H; Zhao G; Hamada J
Neurosci Lett; 2013 Feb; 534():316-21. PubMed ID: 23262078
[TBL] [Abstract][Full Text] [Related]
43. Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.
Richter A; Fischer E; Holz C; Schulze J; Lange S; Sekora A; Knuebel G; Henze L; Roolf C; Murua Escobar H; Junghanss C
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803402
[TBL] [Abstract][Full Text] [Related]
44. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms.
Zitzmann K; Vlotides G; Brand S; Lahm H; Spöttl G; Göke B; Auernhammer CJ
Endocr Relat Cancer; 2012 Jun; 19(3):423-34. PubMed ID: 22499437
[TBL] [Abstract][Full Text] [Related]
45. Inhibition of hedgehog signaling by GANT58 induces apoptosis and shows synergistic antitumor activity with AKT inhibitor in acute T cell leukemia cells.
Hou X; Chen X; Zhang P; Fan Y; Ma A; Pang T; Song Z; Jin Y; Hao W; Liu F; Wang W; Wang Y
Biochimie; 2014 Jun; 101():50-9. PubMed ID: 24394624
[TBL] [Abstract][Full Text] [Related]
46. Hemiasterlin derivative (R)(S)(S)-BF65 and Akt inhibitor MK-2206 synergistically inhibit SKOV3 ovarian cancer cell growth.
Lai WT; Cheng KL; Baruchello R; Rondanin R; Marchetti P; Simoni D; Lee RM; Guh JH; Hsu LC
Biochem Pharmacol; 2016 Aug; 113():12-23. PubMed ID: 27328368
[TBL] [Abstract][Full Text] [Related]
47. A copper chelate induces apoptosis and overcomes multidrug resistance in T-cell acute lymphoblastic leukemia through redox imbalance and inhibition of EGFR/PI3K/Akt expression.
Banerjee K; Das S; Sarkar A; Chatterjee M; Biswas J; Choudhuri SK
Biomed Pharmacother; 2016 Dec; 84():71-92. PubMed ID: 27639544
[TBL] [Abstract][Full Text] [Related]
48. eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206.
Cheng Y; Ren X; Zhang Y; Patel R; Sharma A; Wu H; Robertson GP; Yan L; Rubin E; Yang JM
Cancer Res; 2011 Apr; 71(7):2654-63. PubMed ID: 21307130
[TBL] [Abstract][Full Text] [Related]
49. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.
Wang J; Xu-Monette ZY; Jabbar KJ; Shen Q; Manyam GC; Tzankov A; Visco C; Wang J; Montes-Moreno S; Dybkær K; Tam W; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Ferreri AJM; Wang S; Møller MB; Piris MA; Medeiros LJ; Li Y; Pham LV; Young KH
Am J Pathol; 2017 Aug; 187(8):1700-1716. PubMed ID: 28627414
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma.
Rebecca VW; Massaro RR; Fedorenko IV; Sondak VK; Anderson AR; Kim E; Amaravadi RK; Maria-Engler SS; Messina JL; Gibney GT; Kudchadkar RR; Smalley KS
Pigment Cell Melanoma Res; 2014 May; 27(3):465-78. PubMed ID: 24490764
[TBL] [Abstract][Full Text] [Related]
51. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
Lonetti A; Cappellini A; Spartà AM; Chiarini F; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; McCubrey JA; Martelli AM
Oncotarget; 2015 Apr; 6(12):10399-414. PubMed ID: 25871383
[TBL] [Abstract][Full Text] [Related]
52. Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia.
Konopleva MY; Walter RB; Faderl SH; Jabbour EJ; Zeng Z; Borthakur G; Huang X; Kadia TM; Ruvolo PP; Feliu JB; Lu H; Debose L; Burger JA; Andreeff M; Liu W; Baggerly KA; Kornblau SM; Doyle LA; Estey EH; Kantarjian HM
Clin Cancer Res; 2014 Apr; 20(8):2226-35. PubMed ID: 24583795
[TBL] [Abstract][Full Text] [Related]
53. MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines.
Almhanna K; Cubitt CL; Zhang S; Kazim S; Husain K; Sullivan D; Sebti S; Malafa M
Cancer Biol Ther; 2013 Oct; 14(10):932-6. PubMed ID: 23917345
[TBL] [Abstract][Full Text] [Related]
54. Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer.
Agarwal E; Chaudhuri A; Leiphrakpam PD; Haferbier KL; Brattain MG; Chowdhury S
BMC Cancer; 2014 Mar; 14():145. PubMed ID: 24581231
[TBL] [Abstract][Full Text] [Related]
55. MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance.
Yan ZX; Zheng Z; Xue W; Zhao MZ; Fei XC; Wu LL; Huang LM; Leboeuf C; Janin A; Wang L; Zhao WL
Biomed Res Int; 2015; 2015():197241. PubMed ID: 26436088
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).
Evangelisti C; Evangelisti C; Chiarini F; Lonetti A; Buontempo F; Bressanin D; Cappellini A; Orsini E; McCubrey JA; Martelli AM
Int J Oncol; 2014 Sep; 45(3):909-18. PubMed ID: 24968804
[TBL] [Abstract][Full Text] [Related]
57. Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.
Lynch JT; McEwen R; Crafter C; McDermott U; Garnett MJ; Barry ST; Davies BR
Oncotarget; 2016 Apr; 7(16):22128-39. PubMed ID: 26989080
[TBL] [Abstract][Full Text] [Related]
58. Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.
Ghelli Luserna Di Rorà A; Iacobucci I; Imbrogno E; Papayannidis C; Derenzini E; Ferrari A; Guadagnuolo V; Robustelli V; Parisi S; Sartor C; Abbenante MC; Paolini S; Martinelli G
Oncotarget; 2016 Aug; 7(33):53377-53391. PubMed ID: 27438145
[TBL] [Abstract][Full Text] [Related]
59. Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro.
Somnay Y; Simon K; Harrison AD; Kunnimalaiyaan S; Chen H; Kunnimalaiyaan M
Anticancer Drugs; 2013 Jan; 24(1):66-72. PubMed ID: 23147412
[TBL] [Abstract][Full Text] [Related]
60. Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.
Kunami N; Yotsumoto F; Ishitsuka K; Fukami T; Odawara T; Manabe S; Ishikawa T; Tamura K; Kuroki M; Miyamoto S
Anticancer Res; 2011 Jul; 31(7):2483-8. PubMed ID: 21873163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
